Open AccessPerformance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies
Author(s) -
Inna Sekirov,
Martin Petric,
Erin Carruthers,
David Lawrence,
Tamara Pidduck,
Jesse Kustra,
Jonathan Laley,
Min-Kuang Lee,
Navdeep Chahil,
Annie Mak,
Paul N. Levett,
Emelissa J Mendoza,
Heidi Wood,
Mike Drebot,
Mel Krajden,
Muhammad Morshed
Publication year - 2021
Publication title -
access microbiology
Language(s) - English
Resource type - Journals
ISSN - 2516-8290
DOI - 10.1099/acmi.0.000257
Subject(s) - neutralization , virology , covid-19 , antibody , neutralizing antibody , coronavirus , virus , coronaviridae , biology , medicine , immunology , outbreak , infectious disease (medical specialty) , disease , pathology
We compared neutralization assays using either the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus or surrogate neutralization markers, using characterized sera. We found the results of the neutralization assays 75 % concordant overall and 80 % concordant for samples with high antibody levels. This demonstrates that commercial surrogate SARS-CoV-2 assays offer the potential to assess anti-SARS-CoV-2 antibodies’ neutralizing capacity outside CL-3 laboratory containment.